Objectives. To review all the current evidence of LEF-induced pneumonitis (LEIP) which will help rheumatologists recognize suspected cases of LEIP and to influence clinical guidelines. Methods. Thirty-two reported cases of LEIP (13 males and 19 females) were identified from a literature search and classified using Searles and McKendry's classification criteria. Their clinical characteristics were reviewed. Results. All patients had a history of either exposure to MTX or interstitial lung disease (ILD) or both and all patients had RA. Most patients (82%) had LEIP within the first 20 weeks of initiation of LEF. All patients who had a loading dose LEF and most patients with ILD developed LEIP early (within 12 weeks of exposure). Case mortality was 19%. Two patients had previous MTX-induced pneumonitis (MTX-P) prior to initiation of LEF; both died from LEIP. There was a high mortality in the following groups of patients: diffuse alveolar damage (DAD) on histological examination, pre-existing ILD and ground glass shadowing on high resolution computerised tomography (HRCT). Treatment with cholestyramine did not appear to alter clinical outcome. Conclusions. LEIP usually occurs within the first 20 weeks of initiation of LEF. Clinical features of patients who died were pre-existing ILD, ground glass shadowing on HRCT and DAD on histological examination, and these could be poor prognostic indicators. Patients need to be made aware of this rare complication. LEF should not be used in patients with previous MTX-P and should be used with caution in patients with ILD.
Background
LEF is an immunomodulatory drug and its active metabolite A77 1726 inhibits dehydroorotate dehydrogenase, an enzyme key to pyrimidine synthesis in activated T lymphocytes [1] . In randomized control trials, LEF was comparable with MTX in controlling joint symptoms and slowing radiological progression in patients with active RA [2, 3] . LEF is also effective in the treatment of other autoimmune conditions such as PsA [4] , DM [5] , JCA [6] , sarcoidosis [7] , Crohn's disease [8] and WG [9] . LEFinduced pneumonitis (LEIP) is a rare but serious complication of LEF therapy. Since 2004, the awareness of LEIP has increased following an investigation by the Japanese Health Ministry after the death of five Japanese patients from LEIP [10] and the Committee on the Safety of Medicines (CSMs) also reported 17 cases in UK of which five were fatal. The current British Society for Rheumatology (BSR) guidelines on DMARD therapy [11] published recently are silent on providing clear guidance on the risk of LEIP. In this retrospective case series review, the clinical expression of LEIP is assessed and guidance on the possible risk factors of LEIP is provided.
Patients and methods
Thirty-two reported cases in English literature [12] [13] [14] [15] [16] [17] [18] [19] [20] of LEIP (13 males and 19 females) were identified from Pubmed (Medline), Proquest, Canahl and Embase databases using the following keywords and phrases: leflunomide, pneumonitis, leflunomide pneumonitis, interstitial lung disease (ILD), drug-induced pneumonitis, hypersensitivity pneumonitis and delayed hypersensitivity pneumonitis. The origins of cases were as follows: 10 were from Korea, 6 were from Japan, 1 was from UK, 1 from Germany and 14 were from Australia and New Zealand. Patients who had a clinical course suggestive of drug-induced pneumonitis, i.e. an acute respiratory illness following exposure to LEF in the absence of an infective cause, pulmonary interstitial infiltrates on radiological examination and appearances suggestive of hypersensitivity pneumonitis on histological examination (if available) were included in the study and patients who had an identifiable infective cause for their respiratory symptoms were excluded. Patients were classified using Searles and McKendry's criteria [21] . Eleven patients (34%) were classified as definite, 11 (34%) as probable and 10 (29%) as possible LEIP. Demographic details, previous history of ILD, MTX exposure, treatment regimes and case mortality are shown in Table 1 .
Statistical analysis
The results were analysed using chi-squared and Fisher's exact tests.
Results
All patients had RA. Twenty-six patients (82%) presented with LEIP within the first 20 weeks of initiation of LEF therapy. Thirty-one patients (97%) had a history of MTX exposure. There were 13 patients (41%) on combination therapy (MTX and LEF). Four patients (13%) had loading doses of LEF and they all presented within 12 weeks of exposure to LEF. LEF and MTX were withdrawn in all cases. Steroids were given in 24 (75%) patients, 10 (31%) were treated with antibiotics, 7 (22%) received both steroids and antibiotics and 6 (19%) cases received neither. Patients who received cholestyramine were significantly more likely to have been treated with steroids as well compared with patients who did not receive cholestyramine (P ¼ 0.01). There were six (19%) reported deaths and five of them were on combination therapies: two with MTX and three with oral steroids. Five of the six patients who died had LEIP <20 weeks of LEF exposure.
There were six patients with previous ILD. Two patients had previous MTX-induced pneumonitis (MTX-P) which had resolved prior to the initiation of LEF monotherapy; both presented with LEIP early (<12 weeks of LEF exposure) and both died from LEIP. Half of the patients who died following LEIP had either previous ILD or previous MTX-P. Five of the six patients with previous ILD were on LEF monotherapy. One out of four (25%) patients who had a loading dose of LEF died. There were four patients with other respiratory illnesses such as previous tuberculosis (TB) infection (three patients) and emphysema (one patient); there were no deaths in this group. Mortality in Japanese and Korean patients was identical to Western patients (19% in both groups).
Twenty-four patients had high resolution computerised tomography (HRCT) done during the episode of pneumonitis and the main findings are summarized in Table 2 . The main findings on HRCT were ground glass shadowing, bilateral reticular/interstitial shadowing and honeycombing. Consolidation was reported in one case. Fourteen patients had ground glass opacities; they presented early (median duration 12 weeks), three (21%) were on combination treatment (LEF and MTX), and five of the six deaths were in this group. Five patients had mainly bilateral reticular/interstitial shadowing; they presented early (median duration 12 weeks) and there were no deaths in this group. Four patients had predominantly honeycombing; all had previous MTX exposure, none was on combination therapy, none had previous history of ILD and most of them presented with LEIP after more than a year (median duration of 74 weeks) of treatment with LEF. Histological examination was performed in six cases (three autopsies, two transthoracic routes and one unspecified route). The main histological findings were diffuse alveolar damage (DAD) in three cases and interstitial pneumonia in the rest. All three cases with DAD died.
Discussion
This is the first study to show variations in the clinical expression of LEIP. The question as to whether LEIP is a myth or reality [22] is a foregone conclusion. The temporal relationship between initiation of LEF and onset of pneumonitis makes the diagnosis of LEIP likely. Most of the patients with LEIP had previous MTX exposure which is not surprising because LEF is mostly used as second line therapy to MTX; however, LEIP has been reported in patients without previous MTX exposure [18] . Three of the six patients who died had predominantly DAD on histological examination. Our observations are supported by Sakai et al. [23] who reported similar findings of a high mortality in patients with DAD appearances. Lung biopsies are potentially useful in LEIP in that the finding of DAD (which could be a poor prognostic marker) may lead to aggressive therapy, i.e. high dose steroids and close monitoring, possibly in a high dependency unit in view of a high mortality in this group. However, sampling bias cannot be excluded in that some patients with DAD who did not have lung biopsies done may have survived.
Two patients, who had previous MTX-P which had completely resolved and then started on LEF monotherapy, both had early onset LEIP and both died following LEIP. Saravanan and Kelly [24] in their review article published in this journal in 2006 suggested that it is safe to use LEF in previous MTX-P cases. Although the numbers in this study are small and the conclusion could be better drawn after a case-control study, it appears that previous MTX-P carries a high risk for LEIP (100% mortality in this study) and our advice will be either to avoid or to use LEF with caution in patients with a history of MTX-P. The occurrence of pneumonitis in these two patients with two completely different drugs brings into question whether or not there is a genetic basis for hypersensitivity pneumonitis, i.e. some patients are genetically predisposed to hypersensitivity pneumonitis than others. LEIP is five times more common in Japan and Korea (0.5%) than the West [25] . Japanese and Korean populations who are genetically similar have similar rates of LEIP. This provides indirect evidence of a genetic role in LEF hypersensitivity pneumonitis. Genetic polymorphism associated with MTX metabolism has been shown to influence toxicities of MTX [26, 27] , however, there are no studies that have demonstrated such genetic polymorphism in LEIP. Future studies are needed to investigate the genetic basis of hypersensitivity pneumonitis.
Half of the patients with previous ILD died from LEIP and five of the six patients who died had ground glass opacities on HRCT. Pre-existing ILD and ground glass shadowing could be poor prognostic markers. In this study, mortality was not influenced by whether patients received cholestyramine or not. Our findings bring into question whether cholestyramine has an influence in the clinical course of LEIP taking into account the nature of the pathophysiology of LEIP, i.e. an idiosyncratic hypersensitivity reaction. However, a channelling bias cannot be excluded in that those patients who had severe disease were probably more likely to be given cholestyramine compared with those with disease of a lesser severity. Case mortality rate in our case series was 19% and this is similar to MTX-P which is estimated to be between 17 and 30% [28] [29] [30] [31] . Savage et al. [13] in their case series from New Zealand and Australia reported a case mortality of 14%.
Combination of LEF and MTX has been found to be effective in treatment of RA. Both drugs can induce pneumonitis either as monotherapy or in combination. LEIP and MTX-P are in most cases indistinguishable. Some of the cases of LEIP could be MTX-P. Currently there are no established clinical features that could help distinguish LEIP from MTX-P. LEIP is only recently described and so far published studies and case reports on LEIP use either Kremer [34] criteria. As yet none of these diagnostic criteria have ever been validated, primarily because no gold standard investigation exists to validate the diagnostic criteria against. We do not know how well they perform for either MTX-P or LEIP and this is a potential source of weakness of all studies on drug-induced pneumonitis.
We recently published a paper on MTX-P [35] , and using our findings we have observed some differences in presentation between MTX-P and LEIP. LEIP symptoms tend to appear acutely (median duration of 3 days and the range was 1-10 days), in contrast to our previous study which showed that MTX-P symptoms appear subacutely (median duration 14 days and range 1-56 days) [35] . MTX-P usually occurs within the first year of therapy [36] and in contrast to our findings, which are supported by other researchers [13] , most cases of LEIP occur within the first 20 weeks of treatment. The distinction between LEIP and MTX-P is usually academic because treatment is usually the same, i.e. withdrawal of both drugs and administration of intravenous or oral steroids. Patients with honeycombing on HRCT appear to be presenting much later (median 74 weeks) compared with ground glass shadowing (median 12 weeks). All patients with honeycombing were classified as possible LEIP and these cases could be either exacerbation of pre-existing lung fibrosis rather than LEIP, or honeycombing is a feature of chronic LEF lung toxicity. Most of the pre-existing ILD was based on chest X-ray, which has a low sensitivity and specificity for ILD. Our advice is to consider other differential diagnoses in patients who present with symptoms suggestive of LEIP after 20 weeks of exposure to LEF and honeycombing on HRCT scanning. There was 50% mortality in patients with pre-existing ILD and they presented early onset LEIP. There were no deaths in patients with other pre-existing pulmonary problems such as emphysema and old TB. It appears that the nature of lung disease is important in influencing the outcome.
There are no prospective studies done so far to assess the risk factors of LEIP. An association between lung diseases and DMARDs may be difficult to establish due to the high frequency of pulmonary dysfunction in RA. Dawson et al. [37] reported a prevalence of 20% of fibrosing alveolitis in RA patients. However, evidence that pre-existing ILD is a risk factor for LEIP has become clear. Suissa et al. [38] in their large case-control study concluded that the risk of LEIP was restricted to a subgroup of patients who had either exposure to MTX or had ILD or both and this is supported by our findings. They did not find an increased risk of LEF-inducing pneumonitis in patients who had neither exposure to MTX nor pre-existing ILD. However, there are many limitations to this study such as poor case definition, channelling bias, i.e. those patients who had ILD were more likely to be on LEF than MTX, and reporting bias. A Korean study [15] of more than a thousand patients on LEF found a significant association between pre-existing ILD and LEIP. Nine out of the 16 (56%) patients who sparked an investigation by the Japanese Health Ministry had pre-existing lung disease [10] . The current BSR guidelines on DMARD therapy [11] published recently is silent on advising either caution or avoiding using LEF in patients with pre-existing lung diseases, and we think there is an urgent need to review this. We recommend that LEF should either be used with caution (careful patient education to present early with symptoms that could be LEIP) or avoided altogether in patients with ILD. Although LEF is used in many other conditions, LEIP has so far been reported exclusively in RA patients, this could be a reflection of the fact that LEF is used mostly in RA.
Case selection and reporting biases cannot be excluded from this study. A lot of useful information such as peripheral blood counts, pulmonary function tests, histological examinations and bronchoalveolar lavage were either not done or not reported and we are unable to comment on these. Prospective studies are needed to find out the prevalence of this condition and its risk factors. It would also be important to identify in future studies if it is the severity or nature of the underlying lung disease that influences outcome. Some of our observations are best confirmed by case-control studies. Other cases reported in other languages were not included.
Conclusion
LEIP usually occurs within the first 20 weeks of initiation of LEF therapy. The clinical features of patients who died were preexisting ILD, ground glass opacities on HRCT and DAD on histological examination, and these could be poor prognostic indicators. LEF should not be used in patients with previous MTX-P. In patients with previous ILD, LEF should either be avoided or used with caution. Clinicians need to alert patients to this rare but serious complication of LEF therapy.
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